JG
ANTH

Jefferies Group’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Jefferies Group’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-313
Closed -$8K – 2645
2016
Q3 		$8K Buy
+313
New +$7.89K ﹤0.01% 2161

Other funds holding ANTH

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Jefferies Group's ANTH Position: Q4 2016 in Review

Jefferies Group sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q4 2016, closing a stake of 2,460 shares — an estimated $62K sold.

Jefferies Group first reported a position in ANTH in Q2 2013 and held it in 8 quarters. The position peaked at $505K in Q2 2013. 72 funds tracked by Wall St. Rank hold ANTH as of Q4 2016.

  • Jefferies Group reported no remaining Anthera Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Jefferies Group sold 2,460 Anthera Pharmaceuticals, Inc. shares in Q4 2016, an estimated $62K.
  • Jefferies Group first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and held it in 8 quarters.
  • Jefferies Group's Anthera Pharmaceuticals, Inc. position peaked at $505K in Q2 2013.
  • 72 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q4 2016.

Based on Jefferies Group's 13F filing for Q4 2016, filed 14 Feb 2017.